Latest Compliance News

BPH Global Ltd (ASX, BP8) has initiated strategic discussions with Indonesia’s National Economic Council to deploy its innovative seaweed-based bioremediation solutions targeting pollution from nickel and coal mining operations.

Nova Minerals has priced a US$11.1 million underwritten public offering on NASDAQ, aiming to boost exploration and development at its Estelle Gold and Critical Minerals Project in Alaska.

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

RBR Group Limited invites eligible shareholders to participate in a Share Purchase Plan aiming to raise up to $650,000 by offering shares at a highly discounted price of $0.001 each. The capital raised will support a joint venture, debt repayment, and working capital needs.

Redivium Limited has initiated a comprehensive business review and advisor appointment process aimed at exploring restructuring options to enhance long-term shareholder value and governance.

Macarthur Minerals Limited has updated the timetable for its A$2 million renounceable rights issue, allowing shareholders more time to participate. The company also clarified an earlier announcement, confirming its agreement with Gold Valley Yilgarn Pty Ltd pertains only to the Lake Giles Hematite Project, not the Moonshine Magnetite Project.

Haranga Resources has successfully renewed its Saraya Uranium Project exploration permit in Senegal for another three years, following a positive regulatory audit. This extension secures ongoing exploration of a significant uranium resource with promising prospects.

Mount Hope Mining is poised to launch its maiden drilling campaign at the Mt Hope Project in NSW, targeting three key prospects with over 3,800 metres of drilling planned to convert exploration targets into JORC-compliant resources.

Pact Group Holdings Ltd has requested suspension of its shares from ASX trading as it prepares for removal from the official list, signaling a major shift for investors.

Advanced Health Intelligence has been formally delisted from NASDAQ due to shareholder equity deficiencies but is actively pursuing ASX reinstatement as a critical step toward regaining its dual-listing status.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.

G8 Education faces ASX scrutiny over its handling of sensitive information about a former employee, with the regulator questioning the company’s disclosure practices despite GEM’s insistence of compliance.